SATRALIZUMAB IN PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)

• Research type

  Research Study

• Full title

  A MULTICENTER, SINGLE ARM, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SATRALIZUMAB IN PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)

• IRAS ID

  1003408

• Contact name

  Trial Information Support Line-TISL

• Contact email

  global.rochegenentechtrials@roche.com

• Sponsor organisation

  F Hoffmann-La Roche Ltd

• Eudract number

  2020-003413-35

• REC name

  West of Scotland REC 1

• REC reference

  20/WS/0146

• Date of REC Opinion

  7 Dec 2020

• REC opinion

  Further Information Favourable Opinion